Analyst Expectations For Silence Therapeutics’s Future – Silence Therapeutics (NASDAQ:SLN)

All through the final three months, 7 analysts have evaluated Silence Therapeutics SLN, providing a various set of opinions from bullish to bearish.

The desk under offers a concise overview of latest rankings by analysts, providing insights into the altering sentiments over the previous 30 days and drawing comparisons with the previous months for a holistic perspective.

	Bullish	Considerably Bullish	Detached	Considerably Bearish	Bearish
Complete Rankings	6	1	0	0	0
Final 30D	1	0	0	0	0
1M In the past	0	0	0	0	0
2M In the past	3	1	0	0	0
3M In the past	2	0	0	0	0

The 12-month worth targets, analyzed by analysts, provide insights with a median goal of $65.57, a excessive estimate of $75.00, and a low estimate of $49.00. Surpassing the earlier common worth goal of $63.14, the present common has elevated by 3.85%.

Diving into Analyst Rankings: An In-Depth Exploration

The evaluation of latest analyst actions sheds mild on the notion of Silence Therapeutics by monetary consultants. The next abstract presents key analysts, their latest evaluations, and changes to rankings and worth targets.

Analyst	Analyst Agency	Motion Taken	Score	Present Value Goal	Prior Value Goal
Keay Nakae	Chardan Capital	Maintains	Purchase	$55.00	$55.00
Michael Ulz	Morgan Stanley	Raises	Chubby	$49.00	$45.00
Keay Nakae	Chardan Capital	Raises	Purchase	$55.00	$42.00
Patrick Trucchio	HC Wainwright & Co.	Maintains	Purchase	$75.00	$75.00
Patrick Trucchio	HC Wainwright & Co.	Maintains	Purchase	$75.00	$75.00
Patrick Trucchio	HC Wainwright & Co.	Maintains	Purchase	$75.00	$75.00
Patrick Trucchio	HC Wainwright & Co.	Maintains	Purchase	$75.00	$75.00

Key Insights:

• Motion Taken: Analysts steadily replace their suggestions primarily based on evolving market situations and firm efficiency. Whether or not they ‘Preserve’, ‘Elevate’ or ‘Decrease’ their stance, IT displays their response to latest developments associated to Silence Therapeutics. This Information offers a snapshot of how analysts understand the present state of the corporate.
• Score: Delving into assessments, analysts assign qualitative values, from ‘Outperform’ to ‘Underperform’. These rankings talk expectations for the relative efficiency of Silence Therapeutics in comparison with the broader market.
• Value Targets: Analysts set worth targets as an estimate of a inventory’s future worth. Evaluating the present and prior worth targets offers perception into how analysts’ expectations have modified over time. This Information will be priceless for traders searching for to grasp consensus views on the inventory’s potential future efficiency.

Navigating by means of these analyst evaluations alongside different monetary indicators can contribute to a holistic understanding of Silence Therapeutics’s market standing. Keep knowledgeable and make data-driven selections with our Rankings Desk.

Keep updated on Silence Therapeutics analyst rankings.

If you’re involved in following small-cap inventory information and efficiency you can begin by monitoring IT right here.

About Silence Therapeutics

Silence Therapeutics PLC is a biotechnology firm targeted on discovering and creating novel molecules incorporating short-interfering ribonucleic acid. its pipeline merchandise are; SLN360 remedy designed to quickly block a selected gene’s message that will in any other case set off an undesirable impact. By silencing the LPA gene, the degrees of Lp(a) are lowered, which in flip is predicted to decrease the dangers of coronary heart illnesses, coronary heart assaults, and strokes, and SLN124 remedy goals to quickly silence TMPRSS6, a gene that forestalls the liver from producing a selected hormone that controls iron ranges within the physique hepcidin. As hepcidin will increase, iron ranges within the blood are anticipated to lower, which can improve the manufacturing of wholesome pink blood cells, thereby decreasing anemia.

Understanding the Numbers: Silence Therapeutics’s Funds

Market Capitalization Evaluation: Reflecting a smaller scale, the corporate’s market capitalization is positioned under trade averages. This may very well be attributed to elements akin to progress expectations or operational capability.

Income Progress: Over the three months interval, Silence Therapeutics showcased optimistic efficiency, attaining a income progress fee of 9.07% as of 31 March, 2024. This displays a considerable improve within the firm’s top-line earnings. When in comparison with others within the Health Care sector, the corporate faces challenges, attaining a progress fee decrease than the typical amongst friends.

Internet Margin: The corporate’s web margin is a standout performer, exceeding trade averages. With a formidable web margin of -15.12%, the corporate showcases sturdy profitability and efficient value management.

Return on Fairness (ROE): Silence Therapeutics’s monetary power is mirrored in its distinctive ROE, which exceeds trade averages. With a outstanding ROE of -2.66%, the corporate showcases environment friendly use of fairness capital and robust monetary Health.

Return on Property (ROA): Silence Therapeutics’s monetary power is mirrored in its distinctive ROA, which exceeds trade averages. With a outstanding ROA of -1.3%, the corporate showcases environment friendly use of property and robust monetary Health.

Debt Administration: Silence Therapeutics’s debt-to-equity ratio is under the trade common at 0.0, reflecting a decrease dependency on debt financing and a extra conservative monetary method.

Analyst Rankings: Simplified

Analyst rankings function important indicators of inventory efficiency, supplied by consultants in banking and monetary techniques. These specialists diligently analyze firm monetary statements, take part in convention calls, and have interaction with insiders to generate quarterly rankings for particular person shares.

Some analysts publish their predictions for metrics akin to progress estimates, earnings, and income to offer extra steerage with their rankings. When utilizing analyst rankings, IT is necessary to understand that inventory and sector analysts are additionally human and are solely providing their opinions to traders.

This text was generated by Benzinga’s automated content material engine and reviewed by an editor.